Tamsulosin hydrochloride is a highly selective a 1A -adrenoreceptor antagonist that was developed for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUPS/BPH). Since tamsulosin hydrochloride can have dose-related adverse effects, a controlled release dosage is necessary.
HPMCP and HPMC. In each case, the calculated amount of HPMCP was dispersed in water and then added to Surelease ® . 5% (w/w) HPMC solutions were prepared and stirred overnight and then added to the mixture of HPMCP and Surelease ® . The final coating dispersions were adjusted to obtain ca. 15% (w/w) for the total solid content and stirred throughout the coating process. One kilogram of drug-loaded pellets from the 1000-1190 mm sieve fraction was used for coating. The drug-loaded pellets were coated using a Glatt (GPCG-3) bottom spray fluidized-bed coater and the following conditions: inlet temperature 47Ϯ3°C, outlet temperature 40Ϯ3°C, air flow 70 m 3 /h, nozzle diameter 1.2 mm, and spray rate 6 ml/min. Following the application of the coating solution, the pellets were dried in a coater for an additional 30 min to prevent sticking. The coated pellets were spread onto paper trays and stored at 60°C for 24 h.
In Vitro Dissolution Test Release of tamsulosin hydrochloride from coated pellets was determined using a dissolution apparatus (Vankel VK7000, Cary, NC, U.S.A.) according to the USP XXV paddle method. Hard gelatin capsules (capsule No. 3, Su Heung Capsule Co. Ltd., Korea) were filled with coated pellets containing 0.2 mg drug. The capsules were added to 500 ml simulated gastric fluid without pepsin (adjusted to pH 1.2 with HCl) containing polysorbate 80 (0.003% w/w) at 37Ϯ0.1°C and with a paddle speed of 100 rpm. A sinker was used to prevent capsule flotation. Five-milliliter samples were taken at defined time intervals, and the same volume of simulated gastric fluid was replaced. After 2 h, the solution was replaced with 500 ml simulated intestinal fluids without pancreatin (pH 7.2, phosphate buffer according to the USP without enzyme) and the dissolution testing was continued. Additional samples were taken at 3 and 5 h. Samples were analyzed by HPLC as described in the previous study.
3) Dissolution tests were repeated six times for all formulations and the % drug dissolved was calculated.
Results and Discussion
Experimental Design The experimental runs with independent variables and corresponding responses for the 15 formulations tested are presented in Table 2 . The dependent variables were the cumulative percentages of drug dissolved within 2, 3 and 5 h. In this study, a three-factor, three-level Box-Behnken design was used and the design consists of replicated center points and a set of points lying at the midpoints of each edge of a multidimensional cube that defines the interesting area. Based on the Box-Behnken model, the factor combinations resulted in different drug release rates. Various models, such as Linear, 2FI, Quadratic and Cubic, were fitted to the data for three responses simultaneously using Design Expert software and adequacy, and good fit of the model was tested using analysis of variance (ANOVA). The multiple correlation coefficient (R 2 ), adjusted multiple correlation coefficient (adjusted R 2 ) and the predicted residual sum of square (PRESS), provided by Design-Expert software, were used as factors for selection of adequate models. The lack of fit analysis (data not shown) shows that a quadratic model is appropriate for the description of all responses.
From the results, the quadratic model was selected as a good fit for the model because its PRESS was the smallest. PRESS is a measure of the fit of the model to the points in design; the smaller PRESS the better the model fits to the data points.
11) The quadratic model generated by the design is of the form:
where A 0 is an intercept and A 1 -A 9 are the coefficients of respective factors and their interaction terms. Mathematical relationships in the form of quadratic equations for all responses and their standardized main effects are shown in Tables 3 and 4, respectively. Positive or negative signs before a coefficient in quadratic models indicate a synergistic effect or an antagonistic effect for the factor.
As shown in diffusional pathlength with increasing coating weight gain. Similar results were previously reported by many authors. 3, 12, 13) Therefore, it can be suggested that drug release from the controlled release pellets coated with a blend of HPMCP (X 1 ) and HPMC (X 2 ) was dominated by diffusion through the coated film.
Based on the estimated quadratic equations, 2D contour and 3D response surface plots were obtained for the description of the relationship between the independent variables and the responses and presented in Fig. 1 . The HPMCP content (X 1 ) showed significant synergistic effects (pϽ0.05) on Y 2 and Y 3 , while it showed an insignificant effect on Y 1 . In other words, factor X 1 demonstrated synergistic effects on drug release in dissolution medium at pH 7.2. HPMCP is insoluble in gastric fluid (pH ca. 1.5), but undergoes rapid dissolution above pH 5.5. Therefore, it can be expected that the leaching of HPMCP out of film coatings at pH 7.2 increases the permeability of the coated film, but the underlying mass transport phenomena might be more complex. 14) In comparison with the HPMCP content (X 1 ), the HPMC content (X 2 ) showed significant synergistic effects on all responses, Y 1 , Y 2 and Y 3 . These effects may be attributed to the increased permeability of the coated film due to dissolution of HPMC, since HPMC has pH-independent solubility, in contrast to HPMCP. Accordingly, it has been suggested that HPMC increases the permeability of the coated film, irrespective of the pH of the dissolution medium. 13) These results indicate that drug release from the coated pellets is dominated by diffusion through the coated film. The permeability of the coated film can be controlled by the addition of additives. Moreover, the nature of the additives played an important role in changing the permeability of the coated film. Specifically, pH-dependent permeability could be achieved by using of enteric polymers, such as HPMCP.
Optimization In order to find the level of each independent variable that will lead to an optimized formula- tion, the optimization process was performed for X 1 , X 2 and X 3 using the following target ranges; 15%ՅY 1 Յ30%; 50%ՅY 2 Յ65%; 80%ՅY 3 Յ95%. The target ranges of these responses were determined based on the dissolution profiles of the Harunal ® capsule, a commercial product. The optimization process was performed by graphical and numerical analysis using Design Expert software based on the methodology described by Myers and Montgomery.
15) The optimized levels of each independent variable were based on the criterion of desirability. The optimized levels of HPMCP content (X 1 ), HPMC content (X 2 ) and coating level (X 3 ) were 30%, 15% and 25%, respectively, with a maximum value of desirability of 1.00. Table 5 shows the predicted and observed responses for the optimized formulations, indicating that the release profile of the tamsulosin hydrochloride pellet coated with the optimized formulation was close to the predicted values. The dissolution profiles of the optimized formulation and the commercial product (Harunal ® capsule, Lot no. HRC801, Yamanouchi Pharmaceutical Co. Ltd., Korea) are presented in Fig. 2 . These dissolution profiles were compared using two fit factors, difference factor (f 1 ) and similarity factor ( f 2 ). The calculated values of f 1 and f 2 were 4.6 and 78.7, respectively, indicating that the dissolution profiles of the optimized formulation were comparable to those of the commercial Harunal ® capsule.
Conclusions
In the present study, tamsulosin hydrochloride controlled release pellets were prepared using a blend of HPMCP and HPMC in aqueous dispersions (Surelease ® ). An optimization procedure using the Box-Behnken design gave values for HPMCP content (X 1 ), HPMC content (X 2 ) and coating level (X 3 ) of 30%, 15% and 25%, respectively, and the observed responses of the optimized formulation were very close to the predicted values. Furthermore, calculation of the difference and similarity factors indicated that the dissolution profiles of controlled release pellets coated with the optimized formulation were similar to those of the commercial Harunal ® capsule. 
